At the intersection of human ambition and technological constraint, Arm Holdings CEO Rene Haas has offered a vision in which artificial intelligence becomes medicine's most powerful ally — capable of unravelling the molecular complexity of cancer in ways that neither human researchers nor today's computers can manage alone. Speaking from a company that quietly underpins much of the world's computing infrastructure, Haas frames the current moment as one of immense promise held back by a single, stubborn bottleneck: the world simply cannot yet build chips fast enough to meet the demand its own i